Nephrada · IGAN · Germany · Academic nephrologist · captured by Dr. Anna Becker on 11 Sept 2026 · reviewed by Dr. Marcus Lindqvist on 11 Sept 2026
Verbatim as captured; never edited
Professor at Charité mentioned a patient in the open-label extension who developed recurrent sinopulmonary infections after 14 months and asked whether immunoglobulin monitoring should be more frequent. Reported as an observation, not a formal complaint.
Human-approved by Dr. Marcus Lindqvist on 11 Sept 2026
Potential safety observation: recurrent infections in OLE patient after 14 months; question on IgG monitoring frequency. Flagged for pharmacovigilance handoff.
AI processing disabled
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 3 | 20% | 12.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 5 | 15% | 15.0 |
| Novelty | 3 | 10% | 6.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 3 | 5% | 3.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | High 77 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 11 Sept 2026, 13:05 UTC | Route | MLDr. Marcus Lindqvist | routedTo | — → Safety | Potential adverse event — PV handoff per SOP-PV-014 | UI |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
11 Sept 2026 · Prof. Benedikt Fischer, Charité Berlin · MSL Dr. Anna Becker
Insight
Reviewed 11 Sept 2026 by Dr. Marcus Lindqvist
Safety · Oliver Brandt · due 18 Sept 2026 · In progress
Initiative
Decision
Outcome
Closure